Clinical Trials Logo

Filter by:
NCT ID: NCT05566067 Not yet recruiting - Anesthesia Clinical Trials

Survey of Anesthesiology Residents' Perceptions of Critical Care Medicine as a Career

Start date: December 2023
Phase:
Study type: Observational

This study's goal is to investigate the reasons behind the decline in interest in critical care fellowships among anesthesia residents.

NCT ID: NCT05565105 Not yet recruiting - Clinical trials for Leukemia, Myeloid, Acute

CD34+ Transplants for Leukemia and Lymphoma

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder.

NCT ID: NCT05563766 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.

NCT ID: NCT05561296 Not yet recruiting - Cataract Clinical Trials

Astigmatism Management With Iris-registration Guided Corneal Relaxing Incisions or Toric IOLs During Cataract Surgery

Start date: September 2022
Phase: N/A
Study type: Interventional

Most of the patients presenting for cataract surgery also have pre-existing corneal astigmatism which if left uncorrected can adversely affect visual and refractive outcomes after cataract surgery. Pre-existing astigmatism at the time of cataract surgery can be corrected by either corneal relaxing incisions or implantation of toric IOLs. While the safety and efficacy of these procedures are well established, there are various challenges associated with these techniques that surgeons need to overcome to achieve good outcomes postoperatively. The use of iris registration technology that automatically compensates for cyclotorsion has the potential to improve the alignment accuracy of CRI or toric IOLs. The Cassini Ambient and Catalys Femtosecond Laser incorporate this technology to help cataract surgeons accurately align toric IOLs on the intended axis of implantation or accurately place CRI on the intended meridian. The present study is aimed at evaluating the efficacy of astigmatism correction during femtosecond laser-assisted cataract surgery with Catalys femtosecond laser. The patients will either undergo iris registration guided CRIs or iris registration guided alignment of toric IOLs.

NCT ID: NCT05558527 Not yet recruiting - Anxiety Clinical Trials

The Social Regulation of Threat-related Vigilance and Arousal

Start date: September 2024
Phase: N/A
Study type: Interventional

This study will examine the effects of social support on threat vigilance and arousal using eye tracking. We will also test the moderating effects of trauma and discrimination history.

NCT ID: NCT05558267 Not yet recruiting - Clinical trials for End Stage Kidney Disease

Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease

Start date: July 31, 2024
Phase: N/A
Study type: Interventional

16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration will be measured bi-weekly prior to HD each week during intervention. The primary endpoint will be the change in potassium from baseline. Additional measurements will include assessment of dietary intake, ambulatory blood pressure, occurrence of peri-dialytic symptoms, and per-dialytic vital signs.

NCT ID: NCT05558189 Not yet recruiting - Parkinson Disease Clinical Trials

Vibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients

Start date: August 20, 2024
Phase: N/A
Study type: Interventional

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on refractory post-surgery PD. vCR will be administered with a device called the Stanford Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as levodopa and or deep brain stimulation. Patients will be followed for two years.

NCT ID: NCT05558059 Not yet recruiting - Clinical trials for Retinopathy of Prematurity

Imaging Retinal Vasculature in Infant Eyes

Start date: August 2024
Phase:
Study type: Observational

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.

NCT ID: NCT05557708 Not yet recruiting - Clinical trials for Carcinoma, Small-Cell Lung

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.

NCT ID: NCT05555550 Not yet recruiting - Glioma Clinical Trials

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Start date: July 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.